| Year |
Citation |
Score |
| 2023 |
Busch SE, Simmons DH, Gama E, Du X, Longo F, Gomez CM, Klann E, Hansel C. Overexpression of the autism candidate gene pathologically enhances olivo-cerebellar signaling in mice. Frontiers in Cellular Neuroscience. 17: 1219270. PMID 37545882 DOI: 10.3389/fncel.2023.1219270 |
0.531 |
|
| 2023 |
Longo F, Aryal S, Anastasiades PG, Maltese M, Baimel C, Albanese F, Tabor J, Zhu JD, Oliveira MM, Gastaldo D, Bagni C, Santini E, Tritsch NX, Carter AG, Klann E. Cell-type-specific disruption of cortico-striatal circuitry drives repetitive patterns of behavior in fragile X syndrome model mice. Cell Reports. 42: 112901. PMID 37505982 DOI: 10.1016/j.celrep.2023.112901 |
0.692 |
|
| 2023 |
Mercaldo V, Vidimova B, Gastaldo D, Fernández E, Lo AC, Cencelli G, Pedini G, De Rubeis S, Longo F, Klann E, Smit AB, Grant SGN, Achsel T, Bagni C. Altered striatal actin dynamics drives behavioral inflexibility in a mouse model of fragile X syndrome. Neuron. PMID 36996810 DOI: 10.1016/j.neuron.2023.03.008 |
0.558 |
|
| 2022 |
Kalinowska M, van der Lei MB, Kitiashvili M, Mamcarz M, Oliveira MM, Longo F, Klann E. Deletion of Fmr1 in parvalbumin-expressing neurons results in dysregulated translation and selective behavioral deficits associated with fragile X syndrome. Molecular Autism. 13: 29. PMID 35768828 DOI: 10.1186/s13229-022-00509-2 |
0.598 |
|
| 2022 |
Gross C, Banerjee A, Tiwari D, Longo F, White AR, Allen AG, Schroeder-Carter LM, Krzeski JC, Elsayed NA, Puckett R, Klann E, Rivero RA, Gourley SL, Bassell GJ. Correction to: Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 35701551 DOI: 10.1038/s41386-022-01345-x |
0.516 |
|
| 2022 |
Allen M, Huang BS, Notaras MJ, Lodhi A, Barrio-Alonso E, Lituma PJ, Wolujewicz P, Witztum J, Longo F, Chen M, Greening DW, Klann E, Ross ME, Liston C, Colak D. Spontaneous generation of ASD astrocytes. Molecular Psychiatry. 27: 2369. PMID 35618836 DOI: 10.1038/s41380-022-01606-7 |
0.445 |
|
| 2022 |
Allen M, Huang BS, Notaras MJ, Lodhi A, Barrio-Alonso E, Lituma PJ, Wolujewicz P, Witztum J, Longo F, Chen M, Greening DW, Klann E, Ross ME, Liston C, Colak D. Astrocytes derived from ASD individuals alter behavior and destabilize neuronal activity through aberrant Ca signaling. Molecular Psychiatry. PMID 35365802 DOI: 10.1038/s41380-022-01486-x |
0.531 |
|
| 2021 |
Viaro R, Longo F, Vincenzi F, Varani K, Morari M. L-DOPA promotes striatal dopamine release through D1 receptors and reversal of dopamine transporter. Brain Research. 147583. PMID 34284020 DOI: 10.1016/j.brainres.2021.147583 |
0.439 |
|
| 2021 |
Longo F, Klann E. Reciprocal control of translation and transcription in autism spectrum disorder. Embo Reports. e52110. PMID 33977633 DOI: 10.15252/embr.202052110 |
0.505 |
|
| 2021 |
Aryal S, Longo F, Klann E. Genetic removal of p70 S6K1 corrects coding sequence length-dependent alterations in mRNA translation in fragile X syndrome mice. Proceedings of the National Academy of Sciences of the United States of America. 118. PMID 33906942 DOI: 10.1073/pnas.2001681118 |
0.661 |
|
| 2021 |
Longo F, Mancini M, Ibraheem PL, Aryal S, Mesini C, Patel JC, Penhos E, Rahman N, Mamcarz M, Santini E, Rice ME, Klann E. Cell-type-specific disruption of PERK-eIF2α signaling in dopaminergic neurons alters motor and cognitive function. Molecular Psychiatry. PMID 33879865 DOI: 10.1038/s41380-021-01099-w |
0.671 |
|
| 2021 |
Oliveira MM, Lourenco MV, Longo F, Kasica NP, Yang W, Ureta G, Ferreira DDP, Mendonça PHJ, Bernales S, Ma T, De Felice FG, Klann E, Ferreira ST. Correction of eIF2-dependent defects in brain protein synthesis, synaptic plasticity, and memory in mouse models of Alzheimer's disease. Science Signaling. 14. PMID 33531382 DOI: 10.1126/scisignal.abc5429 |
0.617 |
|
| 2020 |
Shrestha P, Ayata P, Herrero-Vidal P, Longo F, Gastone A, LeDoux JE, Heintz N, Klann E. Cell-type-specific drug-inducible protein synthesis inhibition demonstrates that memory consolidation requires rapid neuronal translation. Nature Neuroscience. PMID 31959934 DOI: 10.1038/S41593-019-0568-Z |
0.649 |
|
| 2019 |
Notaras M, Allen M, Longo F, Volk N, Toth M, Li Jeon N, Klann E, Colak D. UPF2 leads to degradation of dendritically targeted mRNAs to regulate synaptic plasticity and cognitive function. Molecular Psychiatry. PMID 31636381 DOI: 10.1038/S41380-019-0547-5 |
0.587 |
|
| 2019 |
Mercatelli D, Bolognesi P, Frassineti M, Pisanò CA, Longo F, Shimshek DR, Morari M. Leucine-rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes. Pharmacology Research & Perspectives. 7: e00484. PMID 31149340 DOI: 10.1002/Prp2.484 |
0.575 |
|
| 2019 |
Park J, Longo F, Park SJ, Lee S, Bae M, Tyagi R, Han JH, Kim S, Santini E, Klann E, Snyder SH. Inositol polyphosphate multikinase mediates extinction of fear memory. Proceedings of the National Academy of Sciences of the United States of America. PMID 30692248 DOI: 10.1073/Pnas.1812771116 |
0.573 |
|
| 2018 |
Gross C, Banerjee A, Tiwari D, Longo F, White AR, Allen AG, Schroeder-Carter LM, Krzeski JC, Elsayed NA, Puckett R, Klann E, Rivero RA, Gourley SL, Bassell GJ. Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 30061744 DOI: 10.1038/S41386-018-0150-5 |
0.607 |
|
| 2017 |
Santini E, Huynh TN, Longo F, Koo SY, Mojica E, D'Andrea L, Bagni C, Klann E. Reducing eIF4E-eIF4G interactions restores the balance between protein synthesis and actin dynamics in fragile X syndrome model mice. Science Signaling. 10. PMID 29114037 DOI: 10.1126/Scisignal.Aan0665 |
0.717 |
|
| 2017 |
Longo F, Mercatelli D, Novello S, Arcuri L, Brugnoli A, Vincenzi F, Russo I, Berti G, Mabrouk OS, Kennedy RT, Shimshek DR, Varani K, Bubacco L, Greggio E, Morari M. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice. Acta Neuropathologica Communications. 5: 22. PMID 28292328 DOI: 10.1186/S40478-017-0426-8 |
0.72 |
|
| 2017 |
Rimessi A, Pavan C, Ioannidi E, Nigro F, Morganti C, Brugnoli A, Longo F, Gardin C, Ferroni L, Morari M, Vindigni V, Zavan B, Pinton P. Protein Kinase C β: a New Target Therapy to Prevent the Long-Term Atypical Antipsychotics-Induced Weight-Gain. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 28128334 DOI: 10.1038/Npp.2017.20 |
0.524 |
|
| 2016 |
Arcuri L, Viaro R, Bido S, Longo F, Calcagno M, Fernagut PO, Zaveri NT, Calò G, Bezard E, Morari M. Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease. Neurobiology of Disease. PMID 26804029 DOI: 10.1016/J.Nbd.2016.01.016 |
0.577 |
|
| 2015 |
Cristino L, Luongo L, Squillace M, Paolone G, Mango D, Piccinin S, Zianni E, Imperatore R, Iannotta M, Longo F, Errico F, Vescovi AL, Morari M, Maione S, Gardoni F, et al. d-Aspartate oxidase influences glutamatergic system homeostasis in mammalian brain. Neurobiology of Aging. 36: 1890-902. PMID 25771393 DOI: 10.1016/J.Neurobiolaging.2015.02.003 |
0.506 |
|
| 2015 |
Ravani L, Sarpietro MG, Esposito E, Di Stefano A, Sozio P, Calcagno M, Drechsler M, Contado C, Longo F, Giuffrida MC, Castelli F, Morari M, Cortesi R. Lipid nanocarriers containing a levodopa prodrug with potential antiparkinsonian activity. Materials Science & Engineering. C, Materials For Biological Applications. 48: 294-300. PMID 25579926 DOI: 10.1016/J.Msec.2014.12.014 |
0.489 |
|
| 2014 |
Longo F, Russo I, Shimshek DR, Greggio E, Morari M. Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging. Neurobiology of Disease. 71: 62-73. PMID 25107341 DOI: 10.1016/J.Nbd.2014.07.013 |
0.559 |
|
| 2014 |
Cirnaru MD, Marte A, Belluzzi E, Russo I, Gabrielli M, Longo F, Arcuri L, Murru L, Bubacco L, Matteoli M, Fedele E, Sala C, Passafaro M, Morari M, Greggio E, et al. LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex. Frontiers in Molecular Neuroscience. 7: 49. PMID 24904275 DOI: 10.3389/Fnmol.2014.00049 |
0.553 |
|
| 2014 |
Bonito-Oliva A, Pignatelli M, Spigolon G, Yoshitake T, Seiler S, Longo F, Piccinin S, Kehr J, Mercuri NB, Nisticò R, Fisone G. Cognitive impairment and dentate gyrus synaptic dysfunction in experimental parkinsonism. Biological Psychiatry. 75: 701-10. PMID 23541633 DOI: 10.1016/J.Biopsych.2013.02.015 |
0.323 |
|
| 2006 |
Oliveira MM, Lourenco MV, Longo F, De Felice FG, Klann E, Ferreira ST. P3-171: TARGETING TRANSLATION IMPAIRMENT TO RESTORE COGNITIVE DEFICITS IN ALZHEIMER'S DISEASE MODELS Alzheimer's & Dementia. 14: P1133-P1133. DOI: 10.1016/J.Jalz.2018.06.1529 |
0.518 |
|
| Show low-probability matches. |